Cargando…

Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study

BACKGROUND: This study aimed to identify the current risk factors for coronavirus disease 2019 severity and examine its association with medication use. METHODS: We used data from a large United States electronic health record database to conduct an anonymized cohort study of 171,491 patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimbo, Mitsuki, Saito, Sakae, Uematsu, Takayuki, Hanaki, Hideaki, Otori, Katsuya, Shibuya, Kiyoshi, Ando, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401821/
https://www.ncbi.nlm.nih.gov/pubmed/37542210
http://dx.doi.org/10.1186/s12889-023-16401-4
_version_ 1785084748398329856
author Jimbo, Mitsuki
Saito, Sakae
Uematsu, Takayuki
Hanaki, Hideaki
Otori, Katsuya
Shibuya, Kiyoshi
Ando, Wataru
author_facet Jimbo, Mitsuki
Saito, Sakae
Uematsu, Takayuki
Hanaki, Hideaki
Otori, Katsuya
Shibuya, Kiyoshi
Ando, Wataru
author_sort Jimbo, Mitsuki
collection PubMed
description BACKGROUND: This study aimed to identify the current risk factors for coronavirus disease 2019 severity and examine its association with medication use. METHODS: We used data from a large United States electronic health record database to conduct an anonymized cohort study of 171,491 patients with coronavirus disease 2019. The study was conducted from January 1, 2020, to August 27, 2021. Data on age, race, sex, history of diseases, and history of medication prescriptions were analyzed using the Cox proportional hazards model analysis to calculate hazard ratios for hospitalization and severe risk. RESULTS: Factors that increased the risk of hospitalization and critical care were age ≥ 65 years, male sex, type 2 diabetes, hypertension, interstitial pneumonia, and cardiovascular disease. In particular, age ≥ 65 years significantly increased the risk of hospitalization (hazard ratio, 2.81 [95% confidence interval, 2.58–3.07]; P < 0.001) and critical care (hazard ratio, 3.45 [2.88–4.14]; P < 0.001). In contrast, patients with hyperlipidemia had a reduced risk. However, patients with hyperlipidemia who were not taking statins had a significantly increased risk of hospitalization (hazard ratio, 1.24 [1.16–1.34]; P < 0.001). Sodium-glucose cotransporter-2 inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, glucocorticoids, and statins significantly reduced the risk of hospitalization and critical care. The risk of hospitalization and critical care increased in patients of all ethnicities with type 2 diabetes. The factors that significantly increased the risk of hospitalization in all regions were older age, hypertension, chronic obstructive pulmonary disease, and cardiovascular disease. CONCLUSION: This study identified factors that increase or reduce the risk of severe coronavirus disease. The provision of appropriate drug treatment and modification of lifestyle-related risk factors may reduce coronavirus disease severity.
format Online
Article
Text
id pubmed-10401821
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104018212023-08-05 Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study Jimbo, Mitsuki Saito, Sakae Uematsu, Takayuki Hanaki, Hideaki Otori, Katsuya Shibuya, Kiyoshi Ando, Wataru BMC Public Health Research BACKGROUND: This study aimed to identify the current risk factors for coronavirus disease 2019 severity and examine its association with medication use. METHODS: We used data from a large United States electronic health record database to conduct an anonymized cohort study of 171,491 patients with coronavirus disease 2019. The study was conducted from January 1, 2020, to August 27, 2021. Data on age, race, sex, history of diseases, and history of medication prescriptions were analyzed using the Cox proportional hazards model analysis to calculate hazard ratios for hospitalization and severe risk. RESULTS: Factors that increased the risk of hospitalization and critical care were age ≥ 65 years, male sex, type 2 diabetes, hypertension, interstitial pneumonia, and cardiovascular disease. In particular, age ≥ 65 years significantly increased the risk of hospitalization (hazard ratio, 2.81 [95% confidence interval, 2.58–3.07]; P < 0.001) and critical care (hazard ratio, 3.45 [2.88–4.14]; P < 0.001). In contrast, patients with hyperlipidemia had a reduced risk. However, patients with hyperlipidemia who were not taking statins had a significantly increased risk of hospitalization (hazard ratio, 1.24 [1.16–1.34]; P < 0.001). Sodium-glucose cotransporter-2 inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, glucocorticoids, and statins significantly reduced the risk of hospitalization and critical care. The risk of hospitalization and critical care increased in patients of all ethnicities with type 2 diabetes. The factors that significantly increased the risk of hospitalization in all regions were older age, hypertension, chronic obstructive pulmonary disease, and cardiovascular disease. CONCLUSION: This study identified factors that increase or reduce the risk of severe coronavirus disease. The provision of appropriate drug treatment and modification of lifestyle-related risk factors may reduce coronavirus disease severity. BioMed Central 2023-08-04 /pmc/articles/PMC10401821/ /pubmed/37542210 http://dx.doi.org/10.1186/s12889-023-16401-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jimbo, Mitsuki
Saito, Sakae
Uematsu, Takayuki
Hanaki, Hideaki
Otori, Katsuya
Shibuya, Kiyoshi
Ando, Wataru
Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title_full Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title_fullStr Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title_full_unstemmed Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title_short Risk analysis of COVID-19 hospitalization and critical care by race and region in the United States: a cohort study
title_sort risk analysis of covid-19 hospitalization and critical care by race and region in the united states: a cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401821/
https://www.ncbi.nlm.nih.gov/pubmed/37542210
http://dx.doi.org/10.1186/s12889-023-16401-4
work_keys_str_mv AT jimbomitsuki riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT saitosakae riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT uematsutakayuki riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT hanakihideaki riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT otorikatsuya riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT shibuyakiyoshi riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy
AT andowataru riskanalysisofcovid19hospitalizationandcriticalcarebyraceandregionintheunitedstatesacohortstudy